Furthermore, SIGLECs are abnormally expressed in a variety of malignancies, including hepatocellular carcinoma, endometrial cancer, bladder cancer, and colon cancer (26), and CD33 (28) and CD22 were identified as immunotherapeutic targets for acute myeloid leukemia and non-Hodgkin's lymphoma, respectively (29, 30). The gene discussed is CD33; the disease is acute myeloid leukemia.